BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15557756)

  • 1. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors.
    Määttä M; Santala M; Soini Y; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
    Tumour Biol; 2004; 25(4):188-92. PubMed ID: 15557756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
    Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
    Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
    Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
    Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
    Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
    Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
    Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
    Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
    Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines.
    Afzal S; Lalani el-N ; Foulkes WD; Boyce B; Tickle S; Cardillo MR; Baker T; Pignatelli M; Stamp GW
    Lab Invest; 1996 Feb; 74(2):406-21. PubMed ID: 8780160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive correlation between inhibitors of matrix metalloproteinase 1 and matrix metalloproteinases in malignant ovarian tumor tissues.
    Kikkawa F; Tamakoshi K; Nawa A; Shibata K; Yamagata S; Yamagata T; Suganuma N
    Cancer Lett; 1997 Nov; 120(1):109-15. PubMed ID: 9570393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary.
    Okamoto T; Niu R; Yamada S
    Mol Hum Reprod; 2003 Oct; 9(10):569-75. PubMed ID: 12970394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human fetal testis and ovary.
    Robinson LL; Sznajder NA; Riley SC; Anderson RA
    Mol Hum Reprod; 2001 Jul; 7(7):641-8. PubMed ID: 11420387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The expression of matrix metalloproteinases and their tissue inhibitors in pleomorphic adenoma].
    Chen Y; Tian K; Geng N; Yang MZ; Zhang WP
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2005 Jan; 40(1):58-61. PubMed ID: 15774155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
    Rauvala M; Puistola U; Turpeenniemi-Hujanen T
    Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunohistochemical localization of matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) in tuberculous pleuritis].
    Hoheisel G; Sack U; Hui DS; Lai F; Chan KS; Choi CH; Schauer J; Tannapfel A
    Pneumologie; 2004 May; 58(5):305-8. PubMed ID: 15162254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels.
    Davidson B; Reich R; Berner A; Givant-Horwitz V; Goldberg I; Risberg B; Kristensen GB; Trope CG; Bryne M; Kopolovic J; Nesland JM
    Eur J Cancer; 2001 Nov; 37(16):2040-9. PubMed ID: 11597382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of matrix metalloproteinases and related tissue inhibitors in cystic fluids of ovarian tumors.
    Furuya M
    Hokkaido Igaku Zasshi; 1999 Mar; 74(2):145-55. PubMed ID: 10386163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
    Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
    Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
    Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
    Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 expression is associated with progression from vulvar intraepithelial neoplasia to invasive carcinoma.
    Määttä M; Santala M; Soini Y; Turpeenniemi-Hujanen T; Talvensaari-Mattila A
    Acta Obstet Gynecol Scand; 2010 Mar; 89(3):380-4. PubMed ID: 20109015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.